Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CTX-471 |
| Synonyms | |
| Therapy Description |
CTX-471 is an agonistic antibody that binds to CD137 (4-1BB), which potentially activates immune cells resulting in reduced tumor growth (PMID: 32161196). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CTX-471 | CTX471|CTX 471|anti-4-1BB agonistic monoclonal antibody | TNFRSF9 Antibody 36 | CTX-471 is an agonistic antibody that binds to CD137 (4-1BB), which potentially activates immune cells resulting in reduced tumor growth (PMID: 32161196). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03881488 | Phase I | CTX-471 | Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | Completed | USA | 0 |